News Video | Policy | GPs | Hospitals | Medical | Mental Health | Welfare | Search

 


Muscle damage risk from cholesterol-lowering drug rare

16 May 2014

Serious muscle damage risk from widely used cholesterol lowering drug very low in general population: Otago research

New Zealanders taking a higher dose of simvastatin, one of the statin drugs used to prevent heart attacks and strokes, have a greater risk of rhabdomyolysis than people taking a lower dose according to new University of Otago research. However the condition, in which breakdown of muscle tissue can lead to acute kidney failure, is still very rare in both groups.

In a new study published in the journal International Journal of Cardiology, the researchers found that people taking 40mg of simvastatin daily were about five times as likely to develop rhabdomyolysis when compared with people taking 20mg daily.

In absolute terms, the risks were about 11 per 100,000 person-years in people taking 40mg simvastatin and 2 per 100,000 person-years in those taking 20mg.

Study lead investigator Dr Lianne Parkin says recent meta-analyses have clearly shown that the benefits of statins in preventing major cardiovascular events far outweigh any serious adverse effects associated with their use.

“However, these meta-analyses were based on highly selected participants in randomised controlled trials and there was very little information about the risk of rhabdomyolysis in people taking the doses of simvastatin that are recommended for use in New Zealand,” Dr Parkin says.

“While previous research has found a greater risk of serious muscle damage in people taking higher doses of statins, our study is the largest investigation to date of rhabdomyolysis in a general population of simvastatin users and the first to provide separate estimates of risk for 40mg and 20mg simvastatin.”

The researchers used routinely collected health and prescription medicine data to conduct a study based on 313,552 people of all ages who were dispensed simvastatin at any time between 2005 and 2009. Other factors, including age, sex, medical conditions, and other prescription drugs, were taken into account in the analyses.

“Statins are one of the most widely used classes of drugs,” says Dr Parkin, “and it is reassuring to have found a very low risk of rhabdomyolysis in New Zealanders using simvastatin. The greater risk associated with the use of 40mg simvastatin is one of several factors which patients and their doctors might consider when discussing the balance of benefits and risks of cholesterol-lowering treatment, and the most appropriate dose and type of statin to be used.”

The research was funded by Medsafe and the Health Research Council of New Zealand.

Publication details:
Parkin L, Paul C, Herbison GP. Simvastatin dose and risk of rhabdomyolysis: Nested case-control study based on national health and drug dispensing data.

ENDS

© Scoop Media

 
 
 
 
 
Culture Headlines | Health Headlines | Education Headlines

 
Scoop Review Of Books: Q&A: Prue Hyman On ‘Hopes Dashed?’

For Scoop Review of Books, Alison McCulloch interviewed Prue Hyman about her new book, part of the BWB Texts series, Hopes Dashed? The Economics of Gender Inequality More>>

Gordon Campbell: On Chuck Berry (And James Comey, And Bill English)

Back when many people were still treating rock’n’roll as a passing fad – was calypso going to be the new thing? – Chuck Berry knew that it had changed popular music forever. What is even more astonishing is that this 30-ish black r&b musician from a middle class family in St Louis could manage to recreate the world of white teenagers, at a time when the very notion of a “teenager” had just been invented. More>>

Howard Davis Review:
The Baroque Fusion Of L'arpeggiata

Named after a toccata by German composer Girolamo Kapsberger, L'Arpeggiata produces its unmistakable sonority mainly from the resonance of plucked strings, creating a tightly-woven acoustic texture that is both idiosyncratic and immediately identifiable. Director Christina Pluhar engenders this distinctive tonality associated with the ensemble she founded in 2000 by inviting musicians and vocalists from around the world to collaborate on specific projects illuminated by her musicological research. More>>

African Masks And Sculpture: Attic Discovery On Display At Expressions Whirinaki

Ranging from masks studded with nails and shards of glass to statues laden with magical metal, the works are from ethnic groups in nine countries ranging from Ivory Coast to the Democratic Republic of the Congo. More>>

Obituary: Andrew Little Remembers Murray Ball

“Murray mined a rich vein of New Zealand popular culture and exported it to the world. Wal and Dog and all the other Kiwi characters he crafted through Footrot Flats were hugely popular here and in Australia, Europe and North America." More>>

ALSO:

Organised Choas: NZ Fringe Festival 2017 Awards

Three more weeks of organised chaos have come to an end with the Wellington NZ Fringe Arts Festival Awards Ceremony as a chance to celebrate all our Fringe artists for their talent, ingenuity, and chutzpah! More>>

ALSO:

Wellington.Scoop: Wellington Writer Wins $US165,000 Literature Prize

Victoria University of Wellington staff member and alumna Ashleigh Young has won a prestigious Windham-Campbell Literature Prize worth USD$165,000 for her book of essays Can You Tolerate This? More>>

ALSO:

Scoop Review Of Books: We’re All Lab Rats

A couple of years ago, there were reports that Silicon Valley executives were sending their children to tech-free schools. It was a story that dripped of irony: geeks in the heart of techno-utopia rejecting their ideology when it came to their own kids. But the story didn’t catch on, and an awkward question lingered. Why were the engineers of the future desperate to part their gadgets from their children? More>>

  • CensusAtSchool - Most kids have no screen-time limits
  • Netsafe - Half of NZ high school students unsupervised online
  • Get More From Scoop

     
     

    LATEST HEADLINES

     
     
     
     
    Health
    Search Scoop  
     
     
    Powered by Vodafone
    NZ independent news